Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946985 · ClinicalTrials.gov registry record · Phase 4
28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
A Phase 4 study, sponsored by Ortho-McNeil Janssen Scientific Affairs.
- Terminated
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
NCT00946985 is a Phase 4 study that was terminated before completion, run by Ortho-McNeil Janssen Scientific Affairs. The registered enrollment target is 163 participants.
The verdict
NCT00946985, a Phase 4 study, was terminated before completion, sponsored by Ortho-McNeil Janssen Scientific Affairs.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
Study Summary
The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.
Interventions
- DRUG paliperidone palmitate
- DRUG oral risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946985
The ClinicalTrials.gov registry entry for NCT00946985 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ortho-McNeil Janssen Scientific Affairs, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paliperidone palmitate is the first listed.
NCT00946985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946985 about?
NCT00946985 is a clinical study titled "28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years". The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.
What is the current status of trial NCT00946985?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2009-06. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00946985?
The interventions under investigation include: paliperidone palmitate (DRUG), oral risperidone (DRUG).
Who is sponsoring clinical trial NCT00946985?
This trial is sponsored by Ortho-McNeil Janssen Scientific Affairs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.